Department of Justice Declines to Intervene in
Lawsuit against Gilead Sciences Regarding
December 16, 2010 04:18 PM Eastern Time
FOSTER CITY, Calif.--(EON: Enhanced Online News)--Gilead Sciences, Inc. (Nasdaq:GILD) announced today
that, after conducting an investigation, the United States Department of Justice (“DOJ”) has notified the United
States District Court for the Northern District of California “of its decision not to intervene” in a False Claims Act
lawsuit filed by a former employee of CV Therapeutics, Inc. regarding the promotion of Ranexa® (ranolazine
extended release tablets). Gilead acquired CV Therapeutics in April 2009.
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative
therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from
life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North
America, Europe and Australia.
For more information on Gilead Sciences, please visit the company's website at www.gilead.com or call
Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
Gilead Sciences, Inc.
Susan Hubbard, 650-522-5715 (Investors)
Nathan Kaiser, 650-522-1853 (Media)